Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial

Joseph Tauber,1 James Owen,2 Marc Bloomenstein,3 John Hovanesian,4 Mark A Bullimore5 1Tauber Eye Center, Kansas City, MO 64111, USA; 2TLC Laser Eye Centers-La Jolla, La Jolla, CA 92122, USA; 3Schwartz Laser Eye Center, Scottsdale, AZ 85260, USA; 4Harvard Eye Associates, Laguna Hills, CA 92653, USA;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	meibomian gland dysfunction meibomian gland score tear break-up time ocular surface disease index Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3f91330bd0c54af7a38c9a3c7ae54ff6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f91330bd0c54af7a38c9a3c7ae54ff6
record_format	dspace
spelling	oai:doaj.org-article:3f91330bd0c54af7a38c9a3c7ae54ff62021-12-02T12:06:34ZComparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial1177-5483https://doaj.org/article/3f91330bd0c54af7a38c9a3c7ae54ff62020-02-01T00:00:00Zhttps://www.dovepress.com/comparison-of-the-ilux-and-the-lipiflow-for-the-treatment-of-meibomian-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Joseph Tauber,1 James Owen,2 Marc Bloomenstein,3 John Hovanesian,4 Mark A Bullimore5 1Tauber Eye Center, Kansas City, MO 64111, USA; 2TLC Laser Eye Centers-La Jolla, La Jolla, CA 92122, USA; 3Schwartz Laser Eye Center, Scottsdale, AZ 85260, USA; 4Harvard Eye Associates, Laguna Hills, CA 92653, USA; 5University of Houston, College of Optometry, Houston, TX 77204, USACorrespondence: Joseph TauberTauber Eye Center, 4400 Broadway, Suite 202, Kansas City, MO 64111, USATel +1 816 531 9100Fax +1 816 531 9105Email jt@taubereye.comPurpose: To compare the effects of eyelid treatment with the iLUX MGD Treatment System and the LipiFlow Thermal Pulsation System on objective and subjective parameters of meibomian gland function and symptoms.Patients and Methods: In this randomized, open-label, controlled, multicenter clinical trial, both eyes of 142 patients aged ≥ 18 years with Ocular Surface Disease Index (OSDI) scores ≥ 23, total meibomian gland scores (MGS) ≤ 12 in the lower eyelid of each eye, and tear break-up time (TBUT) < 10 s were randomized 1:1 to iLUX or LipiFlow treatment, with stratification by test center. The primary effectiveness endpoints were changes in total MGS (masked) and TBUT from baseline to 4 weeks. The secondary effectiveness endpoint was changed in OSDI score from baseline to 4 weeks.Results: Both devices significantly improved effectiveness outcomes, with no differences between the two devices. At the 4-week visit, mean MGS, TBUT, and OSDI scores improved at least 16.9 ± 11.5, 2.6 ± 3.2 s, and 28.0 ± 22.8, respectively, across treatment groups and treated eyes. Four device/procedure-related events occurred in the iLUX group, compared with none in the LipiFlow group, but there were no device-related adverse events that involved changes in lid margins, eyelids, or lash integrity. Corneal staining, intraocular pressure, and visual acuity did not differ in the two groups.Conclusion: Both treatments produced significant improvements in meibomian gland function and symptoms. For all effectiveness measures, there were no statistically significant differences between the two treatments.Keywords: meibomian gland dysfunction, meibomian gland score, tear break-up time, ocular surface disease indexTauber JOwen JBloomenstein MHovanesian JBullimore MADove Medical Pressarticlemeibomian gland dysfunctionmeibomian gland scoretear break-up timeocular surface disease indexOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 405-418 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	meibomian gland dysfunction meibomian gland score tear break-up time ocular surface disease index Ophthalmology RE1-994
spellingShingle	meibomian gland dysfunction meibomian gland score tear break-up time ocular surface disease index Ophthalmology RE1-994 Tauber J Owen J Bloomenstein M Hovanesian J Bullimore MA Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
description	Joseph Tauber,1 James Owen,2 Marc Bloomenstein,3 John Hovanesian,4 Mark A Bullimore5 1Tauber Eye Center, Kansas City, MO 64111, USA; 2TLC Laser Eye Centers-La Jolla, La Jolla, CA 92122, USA; 3Schwartz Laser Eye Center, Scottsdale, AZ 85260, USA; 4Harvard Eye Associates, Laguna Hills, CA 92653, USA; 5University of Houston, College of Optometry, Houston, TX 77204, USACorrespondence: Joseph TauberTauber Eye Center, 4400 Broadway, Suite 202, Kansas City, MO 64111, USATel +1 816 531 9100Fax +1 816 531 9105Email jt@taubereye.comPurpose: To compare the effects of eyelid treatment with the iLUX MGD Treatment System and the LipiFlow Thermal Pulsation System on objective and subjective parameters of meibomian gland function and symptoms.Patients and Methods: In this randomized, open-label, controlled, multicenter clinical trial, both eyes of 142 patients aged ≥ 18 years with Ocular Surface Disease Index (OSDI) scores ≥ 23, total meibomian gland scores (MGS) ≤ 12 in the lower eyelid of each eye, and tear break-up time (TBUT) < 10 s were randomized 1:1 to iLUX or LipiFlow treatment, with stratification by test center. The primary effectiveness endpoints were changes in total MGS (masked) and TBUT from baseline to 4 weeks. The secondary effectiveness endpoint was changed in OSDI score from baseline to 4 weeks.Results: Both devices significantly improved effectiveness outcomes, with no differences between the two devices. At the 4-week visit, mean MGS, TBUT, and OSDI scores improved at least 16.9 ± 11.5, 2.6 ± 3.2 s, and 28.0 ± 22.8, respectively, across treatment groups and treated eyes. Four device/procedure-related events occurred in the iLUX group, compared with none in the LipiFlow group, but there were no device-related adverse events that involved changes in lid margins, eyelids, or lash integrity. Corneal staining, intraocular pressure, and visual acuity did not differ in the two groups.Conclusion: Both treatments produced significant improvements in meibomian gland function and symptoms. For all effectiveness measures, there were no statistically significant differences between the two treatments.Keywords: meibomian gland dysfunction, meibomian gland score, tear break-up time, ocular surface disease index
format	article
author	Tauber J Owen J Bloomenstein M Hovanesian J Bullimore MA
author_facet	Tauber J Owen J Bloomenstein M Hovanesian J Bullimore MA
author_sort	Tauber J
title	Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
title_short	Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
title_full	Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
title_fullStr	Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
title_full_unstemmed	Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
title_sort	comparison of the ilux and the lipiflow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3f91330bd0c54af7a38c9a3c7ae54ff6
work_keys_str_mv	AT tauberj comparisonoftheiluxandthelipiflowforthetreatmentofmeibomianglanddysfunctionandsymptomsarandomizedclinicaltrial AT owenj comparisonoftheiluxandthelipiflowforthetreatmentofmeibomianglanddysfunctionandsymptomsarandomizedclinicaltrial AT bloomensteinm comparisonoftheiluxandthelipiflowforthetreatmentofmeibomianglanddysfunctionandsymptomsarandomizedclinicaltrial AT hovanesianj comparisonoftheiluxandthelipiflowforthetreatmentofmeibomianglanddysfunctionandsymptomsarandomizedclinicaltrial AT bullimorema comparisonoftheiluxandthelipiflowforthetreatmentofmeibomianglanddysfunctionandsymptomsarandomizedclinicaltrial
_version_	1718394685415751680

Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial

Ejemplares similares